LV
LAVA Therapeutics N.V.
LVTX · NASDAQ
$1.74 -3.87% (-$0.07)
Market Cap $45.8M
P/E Ratio -
Div. Yield -
ROE 108.07%
Piotroski F-Score Weak
2/9Valuation
68 /100
Cheap P/S 9.17x
P/FCF 3.20x
P/B 3.61x
Growth
100 /100
Growing Book val. growth 134.99%
EPS growth N/A
FCF growth N/A
Profitability
30 /100
Weak Gross margin 391.98%
FCF margin 286.37%
Net margin 466.43%
Quality
1 /100
Poor ROIC 47.45%
Asset turnover 0.10x
ROE 108.07%
Debt
57 /100
Moderate Debt/Equity 0.00x
Net debt/EBITDA 3.38x
Current ratio 12.27x
Stability
28 /100
Unstable Beta 0.50x
Profitable years 0
EPS volatility 92.03%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o LVTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Stephen Allen Hurly
Employees
34
Headquarters
Utrecht